Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2023-04-14 | 2023-06-08 | 189659 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2021-07-09 | 2022-10-07 | 142272 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2020-08-19 | 2021-01-26 | 122473 |
| APO-DABIGATRAN | 110MG | CAPSULE | Actual shortage | 2024-11-15 | 2024-11-15 | 243170 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2024-12-05 | 2025-01-24 | 244888 |
| APO-DAPAGLIFLOZIN | 10MG | TABLET | Resolved | 2024-03-08 | 2024-04-19 | 221678 |
| APO-DAPAGLIFLOZIN | 10MG | TABLET | Resolved | 2023-09-01 | 2024-01-05 | 203563 |
| APO-DAPAGLIFLOZIN | 10MG | TABLET | Resolved | 2023-11-06 | 2024-01-05 | 209333 |
| APO-DAPAGLIFLOZIN | 10MG | TABLET | Resolved | 2023-10-27 | 2024-01-05 | 208370 |
| APO-DAPAGLIFLOZIN-METFORMIN | 850MG 5MG | TABLET | Resolved | 2024-12-05 | 2024-12-13 | 244918 |
| APO-DAPAGLIFLOZIN-METFORMIN | 1000MG 5MG | TABLET | Resolved | 2024-06-20 | 2024-08-02 | 231020 |
| APO-DARIFENACIN | 15MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-01-14 | 2022-02-03 | 152758 |
| APO-DARIFENACIN | 7.5MG | TABLET (EXTENDED-RELEASE) | Resolved | 2021-10-01 | 2022-01-24 | 146503 |
| APO-DARIFENACIN | 15MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-01 | 2024-07-05 | 212368 |
| APO-DARIFENACIN | 7.5MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-15 | 2024-10-11 | 213547 |
| APO-DARUNAVIR | 600MG | TABLET | Resolved | 2020-06-04 | 2020-06-26 | 116530 |
| APO-DARUNAVIR | 600MG | TABLET | Resolved | 2024-06-06 | 2024-10-07 | 229752 |
| APO-DASATINIB | 50MG | TABLET | Resolved | 2022-10-21 | 2022-12-17 | 172360 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2022-11-20 | 2022-12-17 | 175315 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2024-09-12 | 2024-09-20 | 237354 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-QUETIAPINE | 25MG | TABLET | Discontinued | 2020-07-10 | 2020-07-10 | 119950 |
| APO-QUININE | 200MG | CAPSULE | Discontinued | 2018-09-08 | 2021-05-10 | 60711 |
| APO-QUININE | 300MG | CAPSULE | Discontinued | 2018-09-08 | 2021-05-10 | 60714 |
| APO-RABEPRAZOLE | 20MG | TABLET (ENTERIC-COATED) | Discontinued | 2019-01-04 | 2019-01-04 | 71201 |
| APO-RABEPRAZOLE | 10MG | TABLET (ENTERIC-COATED) | Discontinued | 2019-01-04 | 2019-01-04 | 71204 |
| APO-RABEPRAZOLE | 10MG | TABLET (ENTERIC-COATED) | Discontinued | 2018-02-23 | 2019-09-12 | 40805 |
| APO-RABEPRAZOLE | 20MG | TABLET (ENTERIC-COATED) | Discontinued | 2018-09-08 | 2018-10-05 | 60717 |
| APO-RAMIPRIL | 1.25MG | CAPSULE | Discontinued | 2018-09-08 | 2019-03-29 | 60720 |
| APO-RANITIDINE TABLET 150MG | 150MG | TABLET | Discontinued | 2018-09-08 | 2018-12-28 | 60726 |
| APO-RANITIDINE TABLET 150MG | 150MG | TABLET | Discontinued | 2018-09-08 | 2019-02-13 | 60723 |
| APO-RANITIDINE TABLET 150MG | 150MG | TABLET | Discontinued | 2019-01-02 | 2019-01-09 | 70810 |
| APO-RANITIDINE TABLET 300MG | 300MG | TABLET | To be discontinued | 2018-09-08 | 2018-09-08 | 60732 |
| APO-RANITIDINE TABLET 300MG | 300MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60729 |
| APO-REPAGLINIDE | Discontinued | 2018-09-08 | 2018-09-15 | 60735 | ||
| APO-REPAGLINIDE | Discontinued | 2018-09-08 | 2018-09-15 | 60738 | ||
| APO-REPAGLINIDE | Discontinued | 2018-09-08 | 2018-09-15 | 60741 | ||
| APO-RILUZOLE | 50MG | TABLET | To be discontinued | 2025-12-02 | 2025-12-02 | 257819 |
| APO-RILUZOLE | 50MG | TABLET | To be discontinued | 2018-09-08 | 2018-09-08 | 60744 |
| APO-RISEDRONATE | 35MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60747 |
| APO-RISEDRONATE | 35MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64965 |